The molecular docking and MMGBSA analysis of the compound DMBP against a panel of lymphoma-associated protein targets—AKT1, HSP90AA1, MTOR, MAPK1, and MDM2—revealed distinct binding affinities and interaction profiles, indicative of its potential as a multi-target therapeutic agent. Here, MAPK1 is linked to lymphoma.